Science and Research

Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes. METHODS: In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis. RESULTS: Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7-35.5) versus non-lung-transplanted pwCF (16.6; 95% CI: 15.4-17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age >40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted versus non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for Pseudomonas aeruginosa infection and poorer lung function). CONCLUSION: SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s <70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.
  • Jung, A.
  • Orenti, A.
  • Dunlevy, F.
  • Aleksejeva, E.
  • Bakkeheim, E.
  • Bobrovnichy, V.
  • Carr, S. B.
  • Colombo, C.
  • Corvol, H.
  • Cosgriff, R.
  • Daneau, G.
  • Dogru, D.
  • Drevinek, P.
  • Vukic, A. D.
  • Fajac, I.
  • Fox, A.
  • Fustik, S.
  • Gulmans, V.
  • Harutyunyan, S.
  • Hatziagorou, E.
  • Kasmi, I.
  • Kayserová, H.
  • Kondratyeva, E.
  • Krivec, U.
  • Makukh, H.
  • Malakauskas, K.
  • McKone, E. F.
  • Mei-Zahav, M.
  • de Monestrol, I.
  • Olesen, H. V.
  • Padoan, R.
  • Parulava, T.
  • Pastor-Vivero, M. D.
  • Pereira, L.
  • Petrova, G.
  • Pfleger, A.
  • Pop, L.
  • van Rens, J. G.
  • Rodic, M.
  • Schlesser, M.
  • Storms, V.
  • Turcu, O.
  • Woz Niacki, L.
  • Yiallouros, P.
  • Zolin, A.
  • Downey, D. G.
  • Naehrlich, L.
Publication details
DOI: 10.1183/23120541.00411-2021
Journal: ERJ Open Res
Number: 4
Work Type: Original
Location: UGMLC
Disease Area: PALI, CFBE
Partner / Member: JLU
Access-Number: 34984210

DZL Engagements

chevron-down